OR WAIT null SECS
BETHESDA, Md. -- The Aeras Global TB Vaccine
Foundation and the David Geffen School of Medicine at UCLA today announced
they have begun the first clinical trial of a live recombinant tuberculosis
vaccine in the U.S.
Six volunteers were inoculated today with the new vaccine
at the Center for Vaccine Development, St. Louis University, Missouri, under
the direction of Dr. Daniel F. Hoft. Volunteers are also being recruited at
another trial site in Winston-Salem, North Carolina, by Piedmont Medical
Research Associates under the direction of Dr. Thomas W. Littlejohn III.
The vaccine, known as rBCG30, was constructed by Dr. Marcus Horwitz and
his research team at the David Geffen School of Medicine at UCLA. The live
vaccine, which uses the current vaccine called BCG (Bacille Calmette-Guerin)
as a delivery vehicle, over-expresses the major protein secreted by the TB
organism. The Aeras Global TB Vaccine Foundation, the world's only
organization dedicated solely to developing and distributing new TB vaccines,
conducted the preclinical development and regulatory activities required to
begin the study to test the vaccine in humans, in collaboration with
"The development of the vaccine required a decade-long effort, and we are
gratified to see the vaccine progress to clinical trials," said Horwitz,
professor of medicine and microbiology, immunology and molecular genetics at
Each year 8 million people develop new cases of TB, and 2 million people
die of the disease -- nearly all of them in the developing world. The current
TB vaccine used throughout most of the world, BCG, is almost a century old and
has limited efficacy. In conjunction with drug therapy, a more effective
vaccine would greatly reduce the TB disease burden around the world.
First developed and tested in TB-susceptible guinea pigs, the new vaccine
was found to be more potent than the commercially available BCG vaccine.
Funding for basic research, animal testing and vaccine characterization at
UCLA was provided by The National Institute of Allergy and Infectious Diseases
(NIAID), part of the National Institutes of Health.
"We are within reach of new vaccines that could not only save millions of
lives, but achieve the longstanding goal of bringing TB under control in the
developing world," said Dr. Jerald Sadoff, president and CEO of Aeras Global TB
Vaccine Foundation, which is sponsoring the human trial with support from the
Bill & Melinda Gates Foundation. "This is the first step in using modern
vaccines to defeat this global pandemic."
The bacterium that causes tuberculosis -- Mycobacterium tuberculosis --
currently infects 2 billion people worldwide, and is the leading killer of
people infected with HIV. TB is an airborne bacterial disease that can spread
through the lungs to the bones and the brain. Most forms of TB can be treated
with drugs, but the complex regimen takes at least six months to complete, and
medicine is not always available in developing countries.
The current clinical trial will enroll 30 healthy adults in the U.S. to
test the safety of the vaccine and the immune response it provokes. After the
trial has been completed, a similar study will be conducted in South Africa,
where Aeras has developed a clinical trial site for TB vaccine studies.
Source: Aeras Global TB Vaccine Foundation